- In May, Bayer AG company announced unveiled its new Solida-1 pharmaceutical production facility in Leverkusen, Germany. Set to become operational in 2024, the USD 311.69 million single-storey facility is positioned to be one of the most advanced pharmaceutical production plants in the world. Solida-1 is part of Bayer’s USD 1.13 billion investment program aimed at strengthening its global pharmaceutical manufacturing network.
- In July, Merck has completed the acquisition of EyeBio, strengthening its ophthalmology pipeline with Restoret, a novel Wnt pathway agonist for diabetic macular edema and neovascular age-related macular degeneration. The deal includes additional preclinical assets targeting retinal diseases. This strategic acquisition diversifies Merck’s late-stage portfolio and supports its vision of advancing innovative treatments for vision-related conditions.
- In November, Clariant presented its latest portfolio of healthcare solutions at the upcoming CPHI India tradeshow, taking place in Delhi NCR from November 26 to 28, 2024. This year’s exhibition will highlight Clariant Health Care’s ‘Made in India’ product range, the capabilities of its Bonthapally facility, and its deep expertise in biologics, generics, and excipient production.
- In June 2024, Carl Roth GmbH & Co. KG’s facility in Karlsruhe, Germany, has been awarded EXCiPACT GMP certification for its role as a supplier of pharmaceutical excipients.
- In December, Dow has partnered with Macquarie Asset Management to establish Diamond Infrastructure Solutions, a new infrastructure provider focusing on operational efficiency and customer acquisition. Macquarie will acquire a 40% stake in select U.S. Gulf Coast assets, with an option to increase to 49%. The deal is expected to generate up to $3 billion in proceeds for Dow
